.
ADAP financial statements
* Numbers in thousands
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
Capitalization * |
296 592 | 4 574 879 969 | 2 723 019 470 | 2 519 220 872 | 845 095 | 281 698 |
EV * |
137 813 | 4 574 795 926 | 2 722 951 091 | 2 519 195 919 | 811 924 | 811 924 |
Stock price $ |
4.19 | 8.86 | 4.66 | 4 | 5.46 | 1.82 |
Number of shares * |
70 786 | 516 352 141 | 584 338 942 | 629 805 218 | 154 779 | 154 779 |
EPS |
-1,01 | 0,00 | 0,00 | 0,00 | -0,84 | -0,84 |
Revenue * |
14 198 | 37 833 | 59 505 | 1 122 | 3 958 | 3 958 |
Net income * |
-71 579 | -70 138 | -95 514 | -137 165 | -130 092 | -130 092 |
Operating profit * |
-72 799 | -80 661 | -82 365 | -139 770 | -133 405 | -133 405 |
Total liabilities * |
68 373 | 78 163 | 29 851 | 57 905 | 109 915 | 109 915 |
Net debt * |
-158 779 | 40 175 | 68 376 | -24 953 | -33 171 | -33 171 |
Total assets * |
234 515 | 281 147 | 276 736 | 181 543 | 451 142 | 451 142 |
Equity * |
166 142 | 202 984 | 246 885 | 123 638 | 341 227 | 341 227 |
Cash and investments * |
181 473 | 208 261 | 205 134 | 89 542 | 368 217 | 368 217 |
Over the past 10 years, the maximum capitalization of Adaptimmune Therapeutics plc is 4 574 879 969, the minimum is 296 592. Maximum net income 0, Minimum net income -137 165. The maximum price of ADAP shares is 8.86, the minimum price is 4.
.
ADAP valuation
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
P/E |
-4,14 | -65 226,80 | -28 509,10 | -18 366,40 | -6,50 | -2,17 |
P/B |
1,79 | 22 538,10 | 11 029,50 | 20 375,80 | 2,48 | 0,83 |
P/S |
20,89 | 120 923,00 | 45 761,20 | 2 245 300,00 | 213,52 | 71,17 |
E/P |
-24% | 0% | 0% | 0% | -15% | -46% |
P/FCF |
-4,87 | -57 671,20 | -24 959,80 | -21 796,20 | -14,96 | -4,99 |
.
ADAP profitability
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
ROE |
-43% | -35% | -39% | -111% | -38% | |
ROA |
-31% | -25% | -35% | -76% | -29% | |
ROIC |
-37% | -39% | -33% | -95% | -32% |